Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).
暂无分享，去创建一个
M. Santis | W. Vervenne | W. Freier | S. Pahernik | M. Los | M. D. De Santis | P. Goebell | M. Bos | M. Michel | M. Indorf | M. Staehler | C. Eichelberg | U. Zimmermann | S. Schirrmacher-Memmel | A. Flörcken | C. van Arkel | K. Hauswald | D. Gottstein | L. F. V. Weikersthal | M. Schenk | L. V. von Weikersthal | C. A. Lerchenmuller | C. V. Arkel | M. Michel | P. J. Goebell | Silke Schirrmacher-Memmel | Dana Gottstein | Marcus Schenk | P. Goebell